Billaud M - Search Results

1

Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase.

Salvatore G, Nagata S, Billaud M, Santoro M, Vecchio G, Pastan I. Salvatore G, et al. Among authors: billaud m. Biochem Biophys Res Commun. 2002 Jun 21;294(4):813-7. doi: 10.1016/S0006-291X(02)00560-0. Biochem Biophys Res Commun. 2002. PMID: 12061779

2

The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.

Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M. Carlomagno F, et al. Among authors: billaud m. Cancer Res. 1997 Feb 1;57(3):391-5. Cancer Res. 1997. PMID: 9012462

3

Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.

Chappuis-Flament S, Pasini A, De Vita G, Ségouffin-Cariou C, Fusco A, Attié T, Lenoir GM, Santoro M, Billaud M. Chappuis-Flament S, et al. Among authors: billaud m. Oncogene. 1998 Dec 3;17(22):2851-61. doi: 10.1038/sj.onc.1202202. Oncogene. 1998. PMID: 9879991

4

Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?

Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M. Takahashi M, et al. Among authors: billaud m. Hum Mutat. 1999;13(4):331-6. doi: 10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU11>3.0.CO;2-#. Hum Mutat. 1999. PMID: 10220148

5

Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.

Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M. Geneste O, et al. Among authors: billaud m. Hum Mol Genet. 1999 Oct;8(11):1989-99. doi: 10.1093/hmg/8.11.1989. Hum Mol Genet. 1999. PMID: 10484767

6

Molecular mechanisms of RET activation in human neoplasia.

Santoro M, Carlomagno F, Melillo RM, Billaud M, Vecchio G, Fusco A. Santoro M, et al. Among authors: billaud m. J Endocrinol Invest. 1999 Nov;22(10):811-9. doi: 10.1007/BF03343650. J Endocrinol Invest. 1999. PMID: 10614534 Review. No abstract available.

7

Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.

De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN, Santoro M. De Vita G, et al. Among authors: billaud m. Cancer Res. 2000 Jul 15;60(14):3727-31. Cancer Res. 2000. PMID: 10919641

8

The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret.

Melillo RM, Carlomagno F, De Vita G, Formisano P, Vecchio G, Fusco A, Billaud M, Santoro M. Melillo RM, et al. Among authors: billaud m. Oncogene. 2001 Jan 11;20(2):209-18. doi: 10.1038/sj.onc.1204049. Oncogene. 2001. PMID: 11313948

9

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I. Melillo RM, et al. Among authors: billaud m. Mol Cell Biol. 2001 Jul;21(13):4177-87. doi: 10.1128/MCB.21.13.4177-4187.2001. Mol Cell Biol. 2001. PMID: 11390647 Free PMC article.

10

The RET receptor: function in development and dysfunction in congenital malformation.

Manié S, Santoro M, Fusco A, Billaud M. Manié S, et al. Among authors: billaud m. Trends Genet. 2001 Oct;17(10):580-9. doi: 10.1016/s0168-9525(01)02420-9. Trends Genet. 2001. PMID: 11585664

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters